Form 4: Equillium Director Martha J. Demski Granted 20,000 Stock Options

Equillium, Inc. director Martha J. Demski was granted 20,000 stock options with an exercise price of $0.39, vesting over twelve months or until the next annual stockholders' meeting.

Summary

• Martha J. Demski, a Director of Equillium, Inc. (EQ), was granted 20,000 Director Stock Options.
• The options have an exercise price of $0.39 per share.
• The grant date for these options was May 21, 2025.
• The options will expire on May 20, 2035.
• Vesting occurs in twelve equal monthly installments starting from the grant date, or fully vests on the date of the Issuer's annual meeting of stockholders following the grant date, whichever comes first.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it represents a standard compensation practice that aligns director interests with shareholders, without indicating any negative operational or financial news. It's a routine event.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $0.39 provides a clear benchmark for the value at which the options become profitable for the director.

Negatives

• The issuance of new stock options can lead to potential future dilution for existing shareholders if the options are exercised.

Future Outlook

The vesting schedule indicates future milestones for the option holder, with full vesting expected by the company's annual meeting of stockholders following the grant date.

Industry Context

This is a standard compensation practice within the biotechnology and pharmaceutical industries, where equity incentives are commonly used to attract and retain qualified directors and executives, aligning their long-term interests with company performance.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director is a related party transaction, as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also improved alignment of director's interests with shareholder value.
• Management: The director (Martha J. Demski) receives equity compensation, incentivizing performance.

Next Steps

• The options will vest in twelve equal monthly installments commencing on May 21, 2025.
• The options will be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.

Key Dates

Keywords

Equillium, EQ, Form 4, SEC Filing, Insider Transaction, Stock Option Grant, Director Compensation, Martha J. Demski, Equity Compensation